To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
231 Current news of Frost & Sullivanrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Companies are exploring new markets for innovative assets to add value to their pipeline, finds Frost & Sullivan
In recent years, the global pharmaceutical and biotechnology industry has outperformed other sectors in terms of stock market indices. The appeal of orphan drugs and systems that reduce the cost of healthcare will continue to attract investors to fund the industry.Analysis from Frost & Sullivan, ...
Innovations in biomaterials, graft design and other technologies have pushed these products to the forefront of the industry, says Frost & Sullivan
Autografts, the gold standard of bone grafts, have several limitations. As a result, new orthobiologics products are being developed for the benefit of patients as well as surgeons. Innovations in biomaterials and graft design have enabled these advanced products that mimic the natural human bone ...
Animal models are an efficient and cost-effective way to understand underlying mechanisms of several human conditions
The use of small animal models in basic and preclinical research is now an integral part of developing and testing new pharmaceutical drugs prior to commercialisation. Small animal imaging is an efficient and cost-effective research platform for the timely validation and commercialisation of ...
Targeted pain drugs that do not have side effects such as constipation and addiction have a huge market awaiting them, says Frost & Sullivan
The pain market is currently dominated by opioid analgesics, which have well-known side effects such as addiction and constipation. However, a $10 billion market exists for a company able to develop a novel, targeted pain therapy that excludes these side effects, indicating the huge opportunity ...
Haemophilia B segment will see high growth over the forecast period, finds Frost & Sullivan
Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to ...
The recently implemented GAIN Act is expected to lure companies back into R&D as well as attract new participants, finds Frost & Sullivan
The growing threat posed by multi-drug resistant gram-negative organisms (MDR-GNBs) is lending a sense of urgency to the development of antibacterial drugs worldwide. Upcoming regulatory reforms to lower R&D costs and provide incentives for new drug identification will create attractive ...
Close competition encourages established manufacturers to broaden the drug pipeline for targeted therapies, finds Frost & Sullivan
Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in the market for its treatment. Further, popular drugs such as Almita and Avastin are nearing their patent expiry in 2015 and 2017 respectively. As such, the lung cancer therapeutics market offers ...
Frost & Sullivan finds that direct to consumer genomics, which were close to absent a decade ago, are currently thriving
As the era of personalized medicine dawns on healthcare, the need to understand an individual’s genetic information through genomic testing has risen. This emerging branch of medicine has given birth to multiple companies that provide genetic tests to help end users understand their genetic ...
Frost & Sullivan says existing competitors’ dominance of the niche market raises entry barriers
The European Hantavirus diagnostics market is growing at a compound annual growth rate (CAGR) of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent. The European market is more robust primarily due to Hantavirus’ high prevalence rates in Russia, Scandinavia, Finland and ...
A US$150 billion healthcare market by 2017, says Frost & Sullivan
The dynamic healthcare landscape across the Asia-Pacific is expected to continue its strong growth momentum in areas of new entities, investments and products, with the accelerated evolution driven by innovation and opportunities afforded by ASEAN. Healthcare delivery across both primary care and ...